Company intelligence / Profile preview

Shulov Innovative Science

Rehovot, Central, Israel

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Completed Phase II clinical study in Herpes labialis (210 participants) with highly encouraging results demonstrating shortened healing time, rapid pain relief, and good safety profile; ZEP-3 has also completed Phase I studies, was well tolerated, and is in Phase II trials for atopic dermatitis and burns, and Phase I/II for lung inflammation

Therapeutic areas: Infectious DiseasesDermatologyPulmonology
Modalities: PeptidesSmall moleculeSynthetic peptide
Industry: Biotech

Drug pipeline

2 assets

ZEP-3

1 more asset in the full pipeline.

Request access →

Partnerships

Long-term supply contract with Israeli Ministry of Health for snake venoms and anti-veninNo large pharma or major biotech disclosed

Beyond the preview

Go deeper on Shulov Innovative Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shulov Innovative Science.

Explore the full profile